Aptamer Research by HKBU Gains FDA Approval
A remarkable breakthrough has emerged from Hong Kong Baptist University (HKBU) and the Shanghai Sixth People's Hospital, where researchers have developed an aptamer aimed at treating X-linked hypophosphatemia (XLH), a rare bone disease. This innovative aptamer, originally designed for osteogenesis imperfecta treatment, has recently received both Orphan Drug Designation and Pediatric Rare Disease Designation from the U.S. Food and Drug Administration (FDA).
Understanding X-Linked Hypophosphatemia
XLH is characterized by low levels of phosphate in the blood, which is essential for healthy bone formation. The root cause of this condition lies in a mutation of the phosphate regulating endopeptidase homolog X-linked (PHEX) gene, resulting in an X-linked dominant inheritance pattern. Children with XLH typically exhibit deformities in the rib cage and analogous growth issues, while adults may suffer from osteomalacia and pseudo-fractures, leading to significant impairment or even permanent disabilities.
Development of the Aptamer
Professor Zhang Ge from HKBU, alongside Professor Zhang Zhenlin from the Shanghai Sixth People's Hospital and Aptacure Therapeutics Ltd., spearheaded the development of a long-acting sclerostin-loop3 oligonucleotide aptamer dedicated to XLH treatment. This aptamer has gained significant recognition, being awarded both Orphan Drug and Pediatric Rare Disease Designations by the FDA, enhancing its prospects for patient availability.
Research Findings and Implications
The research team conducted detailed analyses of serum samples from 51 XLH patients. This study revealed alarming findings: the serum sclerostin levels in patients were approximately four and a half times higher than average levels observed in healthy individuals. Such high levels suggest a substantial inhibition of bone growth associated with sclerostin.
The Role of Sclerostin
Sclerostin is a protein known for obstructing bone formation but simultaneously plays a titanic role in safeguarding the cardiovascular system. Genetic research indicates that a sclerostin deficiency results in increased serum phosphorus and bone mass in mouse models. However, current treatments using monoclonal sclerostin antibodies elevate the risk of severe cardiovascular conditions.
Therapeutic Insights
The research team identified how sclerostin influences bone formation. They discovered that when the loop3 domain of sclerostin is absent, not only does it enhance bone mass and strength, but it also maintains cardiovascular protection. This finding presents an exciting therapeutic target for enhancing bone formation without incurring cardiovascular risks.
Apc001 Aptamer Development
After rigorous screenings, the research identified Apc001, an oligonucleotide aptamer capable of inhibiting sclerostin's loop3 domain. Animal studies displayed promising results where Apc001 led to increased bone formation and significantly elevated blood phosphorus levels in XLH-affected mice. This outcome indicates a potential new therapy for XLH patients, making Apc001 a candidate for precision medication strategies.
FDA Designations and Clinical Advancement
The FDA's Orphan Drug Designation confers vital advantages. It allows reduced clinical trial sample sizes, waives new drug marketing fees, and provides seven years of market exclusivity. Simultaneously, the Pediatric Rare Disease Designation accelerates review processes for these critical therapies. With both designations, Apc001 may expedite its clinical translation and deliver treatment benefits to XLH patients in a more timely manner.
Current Status and Future Plans
Currently, the production of Apc001 is progressing towards pilot-scale completion, and it is undergoing a preclinical toxicological review by an external third party. The research aims to transition Apc001 into clinical trials in both Mainland China and the U.S., signaling a promising future for XLH treatment.
Frequently Asked Questions
What is the significance of the aptamer developed by HKBU?
The aptamer developed seeks to treat X-linked hypophosphatemia, a rare bone disease, and has received important FDA designations that can fast track its development.
How does XLH affect patients?
XLH leads to low phosphate levels impacting bone mineralization, causing various symptoms such as deformities, pain, and reduced mobility in affected individuals.
What is sclerostin, and why is it important?
Sclerostin is a protein that inhibits bone growth; understanding its role allows the development of therapies that can enhance bone formation without cardiovascular risks.
What are the benefits of FDA designations for Apc001?
FDA designations provide advantages like reduced clinical trial sizes, fee exemptions, priority review, and potential market exclusivity, facilitating faster access to treatments.
Where will clinical trials for Apc001 take place?
Clinical trials for Apc001 are scheduled to occur in both Mainland China and the U.S., broadening the study's reach and potential patient benefits.
